Start Over

A panel of three plasma microRNAs for colorectal cancer diagnosis.

Authors :: Tan Y
Lin JJ
Yang X
Gou DM
Fu L
Li FR
Yu XF
Source :: Cancer epidemiology [Cancer Epidemiol] 2019 Jun; Vol. 60, pp. 67-76. Date of Electronic Publication: 2019 Mar 27.
Publication Year :: 2019
Abstract: Background: Differential microRNA (miRNA) expression profiles in plasma or serum were identified, providing foundation for studying their potentially diagnostic role in colorectal cancer (CRC).<br />Methods: We performed S-poly(T) Plus PCR assay to select and validate differentially expressed plasma miRNAs from a sample set including 101 CRC patients, 20 patients with colorectal noncancerous polyps (NCP), and 134 healthy controls. And bioinformatics methods was used to integrated predicted or validated targets of the differentially dysregulated miRNAs and analyzed their overrepresented pathways.<br />Results: After the two-phase selection and validation process, we identified a miRNA panel (miR-144-3p, miR-425-5p, and miR-1260b) with high diagnostic efficiency for CRC; the panel distinguished CRC patients from controls with 93.8% sensitivity and 91.3% specificity. Results indicated that the dysregulated miRNAs in CRC were functionally involved in several key cancer-related pathways, such as axonal guidance, PI3K, and calcium signaling pathways.<br />Conclusions: Our study demonstrated that a plasma 3-miRNA panel may serve as a novel noninvasive biomarker to diagnose CRC. This plasma 3-miRNA panel may be related to CRC development. However, further studies are needed to highlight its theoretical strengths.<br /> (Copyright © 2019. Published by Elsevier Ltd.)